ERASCA INC
ERASNASDAQTrading Snapshot
- Day Range
- $18.59 – $18.90
- 52-Week Range
- $1.33 – $24.28
- Volume
- $5.02B
- Avg Volume
- $5.90B
- Shares Outstanding
- 342.2M
- Next Earnings
- Oct 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $421M
- Last Q Revenue
- $97M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.93
- Dividend Yield
- —
Why Investors Own ERAS
- ✓High-growth profile — revenue up +39.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 29% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ERASCA INC
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
Immuneering update: atebimetinib shows strong Phase 2a survival in 1L pancreatic cancer; Phase 3 recruiting. Click for more on IMRX stock.
Morgan Stanley Maintains Equal-Weight on Erasca, Raises Price Target to $21
Morgan Stanley analyst Sean Laaman maintains Erasca (NASDAQ:ERAS) with a Equal-Weight and raises the price target from $12 to $21.
Erasca: A Credible Rival To Revolution's Daroxonrasib, At A Cheaper Price Point
Erasca, Inc. vs. Revolution Medicines: ERAS-0015 Phase 1 data, valuation gap, Merck deal, funding, and key risks like patents. Click for more on ERAS stock.
Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns
Erasca stock has delivered an extremely large 1 year gain, yet its valuation checks lean expensive, so the current price is testing how much optimism investors are willing to embed into the story this early in its development. Over the past year, Erasca has returned about 13.8x, which puts a lot of expectation into the current share price. Encouraging early data for ERAS-0015 and new collaborations can support high growth expectations, while heavy funding needs for ongoing trials and future...
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has closed its previously announced upsized public offering of 36,142,857 shares of its common stock, including 4,714,285 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. The s
Erasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full?
Erasca (ERAS) has been in focus after updated preliminary Phase 1 data for ERAS-0015 in RAS-mutant solid tumors, including pancreatic cancer, coincided with a sizeable follow-on equity offering and a sharp move in the stock. See our latest analysis for Erasca. The latest ERAS-0015 update and follow-on offering sit against a powerful run in Erasca’s stock, with a 1-day share price return of 8.94%, a 30-day share price return of 38.79%, and a year-to-date share price return of 443.18%. The...